10 results about "EPA - Eicosapentaenoic acid" patented technology

Provided is a renal function maintenance and protection agent comprising as an active ingredient of a triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA), which can be used as a pharmaceutical or food composition.A triglyceride of docosahexaenoic acid (DHA) or eicosapentaenoic acid (EPA) or a mixture of a triglyceride of docosahexaenoic acid (DHA) and a triglyceride of eicosapentaenoic acid (EPA) is used as an active ingredient for renal function maintenance and protection agents.

Botanical extracts are provided, which comprise ethanol extracts of Nannochloropsis algae having between 10wt% and 50wt% polar lipids and between 45wt% and 60wt% fatty acids, wherein the fatty acids comprise more than 10wt% of eicosapentaenoic acid (EPA) as triglyceride conjugates and / or diglyceride conjugates, and less than 15wt% EPA as free fatty acids. EPA level may reach up to 90wt%, and the botanical extract may be fluid at room temperature. Growth conditions are configured, adjusted and monitored to promote EPA formation in the cell vacuoles, resulting in a high proportion of EPA as tri / di-glyceride conjugates, as well as in a high concentration of Ω-3 fatty acids, which merely requires gentle extraction procedures to reach the final products, thereby maintaining the biochemical of the compounds without excessive modifications.

The present invention provides complexes of a specialized pro-resolving mediator (SPM), or a salt, ester, or amide thereof, and a cyclodextrin (CD), wherein the SPM is a hydroxylated, polyunsaturated fatty acid derived from arachidonic acid, eicosapentaenoic acid, docosahexaenoic acid, or docosapentaenoic acid, 20 or 22 carbon atoms in length, with 4, 5 or 6 conjugated double bonds arranged in diene, triene, or tetraene systems or combinations thereof, and related compositions and methods.

The application relates to a microbial preparation passing through the rumen, a preparation method and application thereof. The microbial preparation passing through the rumen comprises microbial powder and a coating material coated on the surface of the microbial powder. The coating material comprises protective fat. The total weight of fatty acids in the microbial preparation passing through the rumen is 100%, the fatty acids comprise 70wt%-80wt% of palmitic acid and stearic acid, <=9wt% of oleic acid, 5wt%-15wt% of polyunsaturated fatty acids and a residual amount of non-target fatty acids, the mass ratio of the palmitic acid to the stearic acid is 1:1-2:1, the polyunsaturated fatty acids are selected from at least one of docosahexaenoic acid, eicosatetraenoic acid and eicosapentaenoic acid, and the mass ratio of the microbial powder to the protective fat is 2:3-3:2. The microbial preparation passing through the rumen described in the application is used as a feed additive for feeding ruminants such as cows, and can realize the dual improvement of the production performance of the cows and the nutrition strengthening of the milk.

Provided herein are Brassica plants that produce one or more of omega-3 docosapentaenoic acid (DHA), docosapentaenoic acid (DPA), and eicosapentaenoic acid (EPA), and methods of making such plants.

This invention discloses a method for preparing fish oil, belonging to the field of deep oil processing technology. The method includes the following steps: crude fish oil is sequentially subjected to transesterification and enrichment to obtain a mixed ester with high contents of eicosapentaenoic acid ester and docosahexaenoic acid ester. Then, in a choline chloride-glycerol eutectic solvent, the mixed ester undergoes a transesterification reaction with glycerol using Lipozyme TL IM catalysis to generate and separate crude fish oil. Finally, impurities are removed to obtain fish oil. This invention completely avoids the use of organic solvents, employs mild reaction conditions, and utilizes the extremely low solubility of the products in the eutectic solvent, resulting in in-situ layering. This simplifies product separation, allows for the recycling of the eutectic solvent, and is economical, environmentally friendly, and suitable for industrial production.

This invention belongs to the fields of biomedicine, marine microbiology, and microbial fermentation, and discloses a high-EPA-producing Schizochytrium fungus and its applications. The Schizochytrium fungus KDW-306 provided by this invention has the accession number CGMCC No. 42323. This Schizochytrium fungus KDW-306 exhibits high biomass, high oil yield, high EPA titer, and high DHA titer, excellent EPA and DHA synthesis capabilities, and excellent production stability and genetic stability through generations, thus well meeting the needs of large-scale industrial production of EPA and DHA.

This invention provides a pharmaceutical composition for improving memory function, relating to the field of pharmaceutical technology. The composition comprises vitamin B6, vitamin B12, lutein, anthocyanins, phosphatidylserine, docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), levodopa, benserazide, and selegiline. Vitamin B6, vitamin B12, lutein, anthocyanins, phosphatidylserine, DHA, and EPA nourish the brain; levodopa, benserazide, and selegiline are used for neuropharmacological treatment; anthocyanins, lutein, and EPA synergistically improve cerebral microcirculation, enhance blood oxygen supply, scavenge free radicals, reduce inflammation, and decrease brain cell aging and necrosis, thereby delaying the process of memory decline; levodopa, benserazide, and selegiline synergistically supplement and protect dopamine, with benserazide enhancing the bioavailability of levodopa and selegiline inhibiting dopamine degradation.

This invention discloses a high-yield fucoxanthin and / or EPA mutant strain of *Phaeodactylum tricornutum*, its breeding method, and its applications. This invention employs ambient pressure room temperature plasma (ARTP) mutagenesis technology, combined with high-throughput flow cytometry Raman spectroscopy, to screen and obtain two mutant strains, which are named *Phaeodactylum tricornutum* (…). Phaeodactylum tricornutum X7 and X20 were deposited on January 13, 2026, at the Guangdong Provincial Microbial Culture Collection Center, 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou, with accession numbers GDMCC No:67643 and GDMCC No:67644. These mutant strains exhibit outstanding fucoxanthin and eicosapentaenoic acid (EPA) synthesis capabilities, providing core germplasm resources for the large-scale, low-cost production of fucoxanthin and EPA from microalgae.